NVCT Stock Analysis: Buy, Sell, or Hold?
NVCT - Nuvectis Pharma, Inc. Common Stock
$21.52
-1.24 (-5.45%)
▼
5d:
+11.44%
30d:
+10.25%
90d:
+151.4%
BUY
HIGH Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Aug 04, 2026
TODAY
Get Alerted When NVCT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: NVCT shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
✅ BUY SIGNAL: NVCT shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
In-depth Analysis How we analyze
Valuation Analysis: NVCT is currently trading at $21.52, which is considered fair relative to its 30-day fair value range of $17.51 to $23.28.
Technical Outlook: Technically, NVCT is in a strong uptrend. Immediate support is located at $18.02, while resistance sits at $23.12. Short-term momentum is weak, with the stock down 5.4% recently.
Market Sentiment: NVCT has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $31.80 (+47.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, NVCT is in a strong uptrend. Immediate support is located at $18.02, while resistance sits at $23.12. Short-term momentum is weak, with the stock down 5.4% recently.
Market Sentiment: NVCT has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $31.80 (+47.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$17.51 -
$23.28
Company Quality Score
61/100
(BUY)
Options IV Signal
37th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
79.2%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Options fairly priced (IV 37th percentile)
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-5.4%)
- BULLISH: Trading 47.8% below Wall St target ($31.80)
Trading Range Analysis
30-Day Trading Range
$17.51 -
$23.28
Current vs Trading Range
FAIR
Expected Move (7 Days)
±$5.79
(26.9%)
Support & Resistance Levels
Support Level
$18.02
Resistance Level
$23.12
Current Trend
Strong Uptrend
Technical data as of
Jul 31, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-21.22
Wall Street Target
$31.80
(+47.8%)
Share & Embed Analysis
Last updated: August 03, 2026 2:16 AM ET
Data refreshes hourly during market hours. Next update: 3:16 AM
Data refreshes hourly during market hours. Next update: 3:16 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NVCT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$89 | 59 HOLD |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 53 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$93 | 46 HOLD |
|
ARVN
Arvinas Inc |
BUY
21 analysts |
$15 | 54 HOLD |
